Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Coronary heart failure, known as congestive heart failure, occurs when the coronary heart muscle does not pump blood properly. Some conditions including narrowing of the arteries in the heart (coronary artery disease) or high blood pressure or stiffness when filling and pumping correctly. In this session, we can roughly discuss intravenous intravenous vasodilators, which are the main purpose of the severity of heart failure, and provide an understanding of survival rates with the help of cardiac resynchronization therapy.

Excessive blood pressure is also known as hypertension. This is a long-term situation where the blood pressure in the arteries continually increases. It has become increasingly common in recent decades. However, it can be a major cause of stroke, coronary heart failure, coronary artery disease, etc. Therefore, it represents a threat to human existence.

Cardiothoracic surgery is the field of medicine that deals with the surgical treatment of the organs of the thoracic cavity, usually the treatment of diseases of the heart, lungs, and other pleural or mediastinal structures. The main goal of cardiac surgery is to prolong the life of the patient by improving the function of the heart. These operations are performed by a cardiac or cardiothoracic surgeon.

Clinical trials are research studies in which participants try out new treatments, tests, or interventions in order to prevent, detect, treat, or manage medical diseases. Clinical studies are divided into two categories:

The heart can be harmed by diabetes or high blood glucose levels. It has become a major issue in the modern generation, raising the risk of a variety of heart ailments such as heart failure and stroke. Simply modifying one's lifestyle can reduce the risk of heart disease.

In Europe and the rest of the world, cardiovascular disease (CVD) is the leading cause of death. Because epidemiologic research has revealed various modifiable predisposing behaviours and personal qualities that, when rectified, have been demonstrated to lessen the likelihood of developing atherosclerotic cardiovascular illnesses, a preventative approach to CVD is feasible and justifiable.

The pharmaceutical industry is one in which medications are discovered, developed, manufactured, and marketed. The pharmaceutical sector has advanced significantly as a result of the introduction of new technology. Clinical trials are being conducted on a number of cardiac contributions to see if they are effective.

Cardiac transplantation has long been a popular treatment option for those who have high-risk or end-stage heart failure. It is a procedure that involves replacing an unhealthy heart with a healthy one. A healthy heart is given to the recipient by a donor.

When the heart begins to stop working, causing the body to receive less blood and oxygen, the condition is known as heart failure. The most common causes are high blood pressure, myocardial infarction, coronary artery disease, etc. The condition tends to get worse over time, but treatments based on a correct diagnosis can help us feel better and live longer.

Several advances in research have helped expand results in all areas of cardiology. New developments in the treatment of cardiogenic shock, new stent technologies, and much more. At the same time, a rapid increase in the population of patients with heart disease is observed. As a result, patient expectations about new developments are also developed. Therefore, the future world of cardiology may have a novel approach.